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Hypertension is emerging as one of the most significant health complications in re-
cent years (1). There has been a marked increase in the use of combinations of antihy-
pertensive drugs as well with complementary mechanisms of action, with the aim of re-
ducing blood pressure levels more rapidly and improving treatment compliance. The
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A simple RP-HPLC method for the quantification of val-
sartan (VAL), amlodipine (AML) and hydrochlorothiazi-
de (HCT) in human plasma was developed and valida-
ted. VAL, AML and HCT were resolved using a Gemini
C18 column and mobile phase gradient starting from 20
% acetonitrile and 80 % 10 mmol L–1 ammonium formate
(V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile
and 30 % 10 mmol L–1 ammonium formate, over 20 min-
utes, with a flow rate of 1 mL min–1. The samples were
purified by protein precipitation and extraction. Telmisar-
tan was used as internal standard. The method was valida-
ted according to USFDA and EMEA guidelines with good
reproducibility and linear responses R = 0.9985 (VAL),
0.9964 (AML), and 0.9971 (HCT). RSDs of intra- and in-
ter-day precision ranged 2.2–8.1 and 4.6–11.7 %, respec-
tively, for all three drugs. Mean extraction recoveries of
three QCs for the triple drug combination were 76.5 (VAL),
72.0 (AML) and 73.0 (HCT) % for human plasma. Alth-
ough the LC-MS/MS method is more sensitive than
HPLC, HPLC is still suitable for preliminary pharmaco-
kinetic study. The experiments performed demostrated
that simultaneous determination of all components of the
triple drug combination in human plasma can be done
by this method. Proposed method can be also used for
guidance to the LC-MS/MS method.
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2009 reappraisal of the European Society of Hypertension/European Society of Cardiol-
ogy Guidelines recommends the use of a triple drug combination that combines a cal-
cium channel blocker, an angiotensin II receptor blocker and a thiazide diuretic as an ef-
ficacious combination for the management of hypertension with high or very high risk.
The combination of valsartan (VAL), amlodipine (AML) and hydrochlorothiazide (HCT)
achieved greater reductions in mean sitting diastolic and systolic blood pressure than
VAL, AML or HCT in monotherapy, with favorable pharmacodynamic and pharmacoki-
netic profiles (2).
Valsartan, which is chemically described as N-(1-oxopentyl)-N-[[2-(1H-tetrazol-5-yl)
[1,1-biphenyl]-4-yl]methyl]-L-valine (Fig. 1a) (3), is a nonpeptide drug reducing blood
pressure by specifically blocking the action of angiotensin II on the angiotensin subtype-
-1 receptor. Peak plasma levels (2–4 mg mL–1) are reached after 2 h of oral administration
(160 mg) and then decline with a terminal half-life ranging 3–7 h (4, 5). The drug is mini-
mally metabolized and excreted largely (about 80 %) unchanged (6). Amlodipine is 3-
-ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-
-pyridinedicarboxylate, monobenzene sulphonate (Fig. 1b) and acts by inhibiting the en-
try of calcium ions to the vascular smooth muscle of the resistance arterioles. Direct re-
laxant effects cause reductions in peripheral vascular resistance and blood pressure. Hy-
drochlorothiazide, 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonami-
de (Fig. 1c), is a thiazide diuretic commonly used in combination with other antihyper-
tensive agents, including angiotensin II receptor blockers (ARBs) (7). Hydrochlorothia-
zide is known to activate the renin-angiotensin-aldosterone system (RAAS), providing a
strong rationale for the combination of an ARB with HCT (8).
Several HPLC and HPLC-MS methods have been described for the determination of
VAL (1, 9 and 10), AML (11, 12) and HCT (13) alone in human plasma. There are also re-
46
R. N. Sharma and S. S. Pancholi: Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine




































Fig. 1. Structures of: a) valsartan, b) amlodipine besylate, c) hydrochlorothiazide and d) telmisartan
(IS).
ports of methods for simultaneous estimation of VAL and HCT in human plasma (14)
and VAL and AML (15) in rat lever perfusion, but no method has been reported so far
for simultaneous estimation of VAL, AML and HCT in human plasma. Hence, we aimed
to develop and validate a simple RP-HPLC method for the triple drug combination of
valsartan, amlodipine and hydrochlorothiazide in human plasma that could be used for
pharmacokinetic studies and therapeutic drug monitoring.
EXPERIMENTAL
Chemicals and materials
VALwas procured as a gift sample from Dr. Reddy’s Laboratory (India) while AML,
TEL (IS) and HCT were obtained as gift samples from Torrent Pharma Ltd. (India). Me-
thanol, acetonitrile and water of HPLC grade were supplied by Merck Chemicals Ltd.
(India). Ammonium formate and formic acid of AR grade were procured from Spectro-
chem Pvt. Ltd. (India). Human blood plasma was obtained from the blood bank (India).
Apparatus and chromatographic conditions
Chromatographic separations were performed on a Shimadzu (Japan) HPLC system
(LC-2010CHT) using Gemini C18 (250 ´ 4.6 mm i.d. 5 mm particle size) column (Pheno-
menex®, USA), protected with a C18 (4 ´ 2 mm i.d.) precolumn, maintained at 35 °C. The
mobile phase component ratio was managed using the LC Solution Software (Version
1.2) gradient mode from 20 % acetonitrile and 80 % 10 mmol L–1 ammonium formate
(V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L–1 ammo-
nium formate over 20 minutes with a flow rate of 1 mL min–1. The sample (40 mL) was
injected with an auto sampler maintained at 15 °C and detection was carried out at 254
nm using a photodiode array (PDA) detector.
Standard solutions
Standard stock solutions (100 mg mL–1) for VAL, AML and HCT were prepared sepa-
rately by dissolving appropriate amounts of respective drugs in methanol. These were
diluted with methanol to obtain solutions of 10 mg mL–1 (VAL) and 1 mg mL–1 AML and
HCT. The solutions were mixed and volumes were made up to 10 mL in volumetric
flasks to get mixed aqueous solutions of 1–80 mg mL–1 VAL, 0.12–4 mg mL–1 AML and
0.1–8 mg mL–1 HCT.
Calibration standards and QC samples
Calibration standards (CS1-CS8) and QC samples were prepared as 5 % spiked tha-
wed plasma samples, to which the internal standard (IS) (telmisartan) aqueous solution
(10 mg mL–1) was added. The solutions were vortexed for 1 minute and the final concen-
tration range of 50–4000 ng mL–1 VAL, 6–200 ng mL–1 AML and 5–400 ng mL–1 HCT in
plasma was obtained. Three quality control samples LQC, MQC and HQC (150, 600 and
3000 ng mL–1) VAL, (18, 30 and 150 ng mL–1) AML, and (15, 60 and 300 ng mL–1) HCT
were also prepared.
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Plasma sample
The plasma sample was prepared by adding 1 mL mixture of methanol/acetonitrile
(50:50, V/V) as a protein precipitating solvent. After adding 15 mL of IS and vortexing
for 3 minutes, the mixture was centrifuged at 10000 rpm for 10 minutes. The supernatant
was filtered in a glass tube to evaporate the solvent under nitrogen. Finally, dried resi-
due was reconstituted with 0.5 mL mobile phase, filtered and transferred to the auto sam-
pler glass vials for RP-HPLC analysis.
Method validation
The developed method was validated according to USFDA and EMEA bioanalytical
guidelines (16, 17), for the parameters such as linearity, specificity, selectivity, sensitivity,
precision, accuracy, stability and robustness.
Linearity. – Peak area ratios of analyte to IS vs. analyte concentration in the range
50–4000 ng mL–1 (VAL), 6–200 ng mL–1 (AML) and 5–400 ng mL–1 (HCT) were plotted.
The slope, intercept and correlation coefficient were calculated for each standard line.
Specificity and selectivity. – Specificity and selectivity of the method were investiga-
ted by analyzing six different lots of blank plasma and the concentration of all three ana-
lytes at LQC level. Plasma samples were prepared as per the method described in the
sample preparation section.
Sensitivity. – Sensitivity data was evaluated by analyzing six sets of matrix samples
spiked with 50 ng mL–1 VAL, 6 ng mL–1 AML, 5 ng mL–1 HCT (LLOQ), prepared by the
procedure described for the QC sample preparation. The analyte area response at the
LLOQ should be at least 5 times the blank response. Analyte calculated concentration
should be identifiable and reproducible with a precision of  20.0 % and accuracy of
80.0–120.0 %
Limit of detection and limit of quantitation. – The limit of detection (LOD) and limit of
quantitation (LOQ) of the method were determined by the signal to noise ratio. The de-
tection and quantitation limits were determined as the lowest concentration level result-
ing in the peak area of three times and ten times of the base line noise, respectively.
Precision. – To establish intra-day accuracy and precision, six replicates of each
LLOQ, LQC, MQC and HQC samples of VAL, AML and HCT were analyzed in a single
analytical run on the same day and on different days for inter-day different runs.
Extraction recovery. – The extraction efficiency of VAL, AML, HCT and IS were deter-
mined by comparing the peak areas measured after extraction of plasma samples in trip-
licate at three concentrations (LQC, MQC and HQC) with those found after direct injec-
tion of aqueous (un-extracted) samples into the chromatographic system at the same con-
centration levels.
Stability. – Sample stability in terms of short-term process stability and freeze-thaw
stability were tested by analyzing QC samples of VAL, HCT, AML and IS at LQC and
HQC levels while long-term stability was tested at LQC, MQC and HQC levels. The
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freeze-thaw stability (24 h at –20 °C for three cycles), short-term or bench-top stability
(24 h, room temperature) and long-term stability (7 days at –20 °C) were calculated. The
LQC and HQC samples were stored at –15 °C for 24 h to measure the stability of sam-
ples processed in the autosampler. Stock solutions of VAL, HCT, AML and IS (100 mg
mL–1) were stored at room temperature for 24 h and at 2–8 °C for 7 days, and the stabil-
ity was evaluated after analyzing them at the ULOQ level.
Robustness. – The robustness of the method was checked by evaluating the system
suitability parameters obtained after small changes in the mobile phase composition, in-
jection volume, flow rate and column temperature at three levels of analytes.
Determination of VAL, AML and HCT in spiked human plasma
Validated RP-HPLC method was applied to the analysis of processed plasma sam-
ples, spiked with VAL (50–4000 ng mL–1), AML (6–200 ng mL–1) and HCT (5–400 ng mL–1).
Three different concentration samples other than quality control concentrations were




Some important parameters, viz. pH (2–7) of the mobile phase, concentration of the
acid or buffer (ammonium acetate and ammonium formate) solution, percentage and
type of the organic modifier (acetonitrile and methanol), different columns (CN column,
C8 and C18), flow rates (0.5 to 2.0 mL min–1) were attempted for good chromatographic
separation of valsartan, amlodipine and hydrochlorothiazide and IS (telmisartan) indi-
vidually. Trials have shown that the acidic mobile phase with a reverse phase C18 col-
umn gives symmetric and sharp peaks. For this reason, 10 mmol L–1 ammonium for-
mate solution was preferred as acidic buffer solution. Methanol was not sufficient to
resolve VAL, AML, HCT and IS, so acetonitrile was introduced for its high eluting po-
wer. When buffer pH was changed from 2.0 to 3.5 and from 7.0 to 3.5, the resolution was
much better with decreasing peak tailing. Initially, the isocratic mobile phase with differ-
ent combinations of methanol, acetonitrile and buffer was tried but the best results were
obtained by time programming (gradient mode) from 20 % acetonitrile and 80 % buffer
to 70 % acetonitrile and 30 % buffer within 20 min with a 1 mL min–1 flow rate. Reten-
tion times under these conditions were 5.92, 11.61, 17.64 and 18.97 for HCT, AML, VAL
and IS, respectively (Fig. 2). The 254 nm wavelength was set for the quantitative analysis
of all drugs. Although high absorption was observed at the wavelength of 221 nm for all
drugs, it was not selected due to increased interference of background noise.
Physicochemical properties and structural similarity prompted us to select telmisar-
tan as internal standard for this method. Looking towards the low log P value of analy-
tes, we tried the protein precipitation method to extract VAL, AML and HCT along with
IS (7). A combination of 50 % methanol and 50 % acetonitrile was selected because of the
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high extraction power for VAL, AML and HCT and IS. In extracted samples, endoge-
nous plasma components did not produce any interfering peaks within the retention
time of the analytes and IS, as shown in Fig. 2.
Method validation
System suitability. – The system suitability test was an integral part of the chromato-
graphic method development and was used to verify that the system was adequate for
the analysis to be performed. The results obtained after six replicate injections of MQC
were within the RSD of 15 % for area ratios of VAL, AML and HCT to IS. The suitability
of the chromatographic system was also demonstrated by the retention time, resolution,
theoretical plate, tailing factor and capacity factor values (Table I).
Linearity. – Linearity was observed in the concentration range 50–4000 ng mL–1 for
VAL, 6–200 ng mL–1 for AML and 5–400 ng mL–1 for HCT, indicating its suitability for
analysis. Calibration curves depict excellent correlations for VAL (R = 0.9985 ± 0.0002),
AML (R = 0.9964 ± 0.0018) and HCT (R = 0.9971 ± 0.0005) (Table II). The back calculated
nominal concentration of calibrations standards was within the range of 98.8–112.3 (VAL),
98.7–103.6 (AML) and 98.7–114.8 % (HCT).
Specificity and selectivity. – No endogenous source of interference was observed at
the retention time of analytes in any of the six lots of plasma when compared to blank
and QC samples. Typical chromatograms obtained from blank plasma and plasma sam-
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Fig. 2. Chromatogram of VAL, AML and HCT
with IS at 254 nm: a) MQC, b) LQC, c) blank
human plasma.
ples containing LQC of VAL, AML and HCT are presented in Figs. 2b and c. Also, the
peak purity plot for VAL, AML, HCT and IS (Fig. 3) shows the peak purity index of
nearly 1 for each (Table I) and no other peaks co-eluted with analyte.
Sensitivity. – The RSD and mean measured concentration at the LLOQ level were
found to be 5.8 and 109.6 % for VAL, 6.4 and 104.2 % for AML and 6.7 and 109.3 % for
HCT, respectively. The lowest concentrations of 20 ng mL–1 for VAL, 6 ng mL–1 for AML
and 5 ng mL–1 for HCT were selected as LOQ. The LOD measured for this method was
7, 2 and 2 ng mL–1 for VAL, AML and HCT, respectively.
Accuracy and precision. – The accuracy and precision were suggested by means of the
concentration found and RSD, respectively at four QC samples for VAL (50, 150, 600 and
3000 ng mL–1), AML (6, 18, 30 and 150 ng mL–1) and HCT (5, 15, 60 and 300 ng mL–1)
(Table III).
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Table II. Linear regression data

























a Mean ± SD (RSD, %), n = 5.
Table I. System suitability parameters
Parameter HCT AML VAL IS
Retention time (tR) (min) 5.92 11.61 17.64 18.97
Resolution (Rs) 7.23 13.42 23.53 4.25
Number of theoretical plates (N) 20589 45688 56725 52990
Tailing factor (Tf) 0.79 1.23 1.31 1.39
Height equivalent to theoretical plate (HETP) (mm) 12.14 5.47 4.41 4.72
Capacity factor (k’) 1.14 3.21 5.39 5.87
Selectivity (a)a 2.82 1.68 1.09
Peak purity index 1.000 0.999 0.999 1.000
a With respect to succeeding peak.
The mean for intra- and inter-run accuracy ranged 101–108 and 102–108 % for VAL,
AML and HCT. RSD values for intra- and inter-run precision were 2–6 and 5–10 % (VAL),
6–8 and 9–12 % (AML) and 7–8 and 9–12 % (HCT). The across mean RSD and accuracy
was 4.1 and 101.8 % (VAL), 6.6 and 104.9 % (AML) and 7.4 and 104.4 % (HCT).
Extraction recovery. – The mean recovery ± RSD across three concentrations of
76.5 ± 2.1 % (VAL), 72.0 ± 5.2 % (AML), 73.0 ± 4.7 % (HCT) and 73.4 ± 5.1 % for internal
standard suggested good extraction recovery (Table IV).
Stability. – Stability tests of the analytes were designed to cover the expected condi-
tions of handling clinical or preclinical samples (Table V). No significant loss of analytes
in stock solution was observed when stored at room temperature and 2–8 °C, respec-
tively, and analyzed at the ULOQ level. Stock solutions of VAL, AML, HCT and IS were
stable for at least 7 days and the mean change was less than 10 %. During withdrawal
from the freezer and preparation, the samples were found stable with the mean concen-
tration change of –0.8 (LQC) and –0.2 % (HQC) of VAL, –1.0 (LQC) and –0.6 % (HQC) of
AML and, –1.0 (LQC) and –0.9 % (HQC) of HCT. The extracted drug samples were sta-
ble at 15 °C for at least 24 h in the autosampler. Mean changes of concentration values at
LQC and HQC levels after the third cycle of freeze-thaw stability studies were –0.6 and
–0.8 (VAL), –1.8 and –1.4 (AML) and –0.6 and –1.8 % (HCT). The QC samples were stable
at –20 °C for 7 days (long term); the results showed no significant loss of analytes.
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Fig. 3. Peak purity curve of: a) HCT, b) AML, c) VAL and d) IS by PDA detector.
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Table III. Intra-day and inter-day precision and accuracy data
Nominal conc.
(ng mL–1)







50.00 53.51 ± 2.94 101.8 ± 4.9 51.66 ± 5.09 103.3 ± 8.1
150.00 152.69 ± 6.39 101.8 ± 3.2 154.16 ± 8.85 102.8 ± 4.9
600.00 606.68 ± 17.47 101.1 ± 2.2 615.65 ± 37.23 101.7 ± 4.3
3000.00 3071.89 ± 137.71 102.4 ± 4.6 3054.69 ± 175.08 107.0 ± 5.1
Across mean 101.8 ± 0.5 103.7 ± 2.3
Amlodipine
6.00 6.53 ± 0.49 107.9 ± 6.9 6.47 ± 0.76 108.0 ± 8.6
18.00 18.54 ± 1.19 103.0 ± 5.8 18.26 ± 1.84 101.5 ± 7.4
30.00 31.57 ± 2.12 105.2 ± 5.5 31.32 ± 3.01 104.4 ± 6.9
150.00 155.36 ± 8.88 103.6 ± 4.2 151.16 ± 13.90 103.8 ± 6.3
Across mean 104.9 ± 2.2 104.4 ± 2.7
Hydrochlorothiazide
5.00 5.23 ± 0.42 104.7 ± 6.4 5.22 ± 0.61 104.4 ± 9.2
15.00 15.75 ± 1.14 105.1 ± 5.1 15.40 ± 1.44 102.7 ± 7.1
60.00 62.93 ± 4.19 104.9 ± 4.3 62.35 ± 3.36 107.8 ± 8.6
300.00 308.82 ± 22.89 102.9 ± 6.3 314.15 ± 14.35 104.8 ± 7.5
Across mean 104.4 ± 1.0 104.9 ± 2.1
a Mean ± SD, n = 6.
Table IV. Extraction recovery data from human plasma
Analyte Nominal concentration (ng mL–1) Recovery (%) RSD (%)a
Valsartan 150.0 76.5 4.7
600.0 74.9 3.2
3000.0 78.1 7.7
Across mean 76.5 2.1
Amlodipine 18.0 73.9 2.8
30.0 67.7 8.3
150.0 74.3 8.4
Across mean 72.0 5.2
Hydrochlorothiazide 15.0 69.5 5.4
60.0 76.4 4.4
300.0 73.2 4.2
Across mean 73.0 4.7
IS 500.0 73.4 5.1
a n = 6.
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stability at RT for
24 h
VAL 4000.0 101.4 ± 2.1 100.1 ± 2.6
AML 200.0 101.9 ± 2.8 100.8 ± 3.1
HCT 400.0 100.8 ± 2.7 99.8 ± 3.1
IS 1000.0 101.2 ± 3.1 100.1 ± 1.7
Main stock solution
stability at 2–8 °C
for 7 days
VAL 4000.0 102.3 ± 2.4 101.2 ± 1.8
AML 200.0 101.8 ± 2.3 100.9 ± 2.7
HCT 400.0 101.9 ± 2.5 100.9 ± 2.4
IS 1000.0 102.0 ± 2.4 101.2 ± 1.8
Bench top stability
at RT for 24 h
VAL
150.0 99.1 ± 4.3 98.3 ± 5.1
3000.0 103.6 ± 6.6 103.4 ± 7.2
AML
18.0 102.8 ± 4.4 101.7 ± 3.1
150.0 99.3 ± 4.7 98.7 ± 5.1
HCT
15.0 102.7 ± 5.6 101.7 ± 6.8
300.0 99.8 ± 3.3 98.9 ± 4.8
Process stability at
15 °C for 24 h
VAL
150.0 99.3 ± 5.4 98.8 ± 5.8
3000.0 101.4 ± 3.3 100.7 ± 4.9
AML
18.0 102.2 ± 4.3 102.3 ± 2.2
150.0 99.8 ± 0.6 100.0 ± 0.7
HCT
15.0 101.0 ± 5.6 100.8 ± 6.4
300.0 99.8 ± 3.1 99.1 ± 3.9
Freeze thaw at
–20 °C for 24 h
(three cycles)
VAL
150.0 98.7 ± 3.7 98.1 ± 4.6
3000.0 102.5 ± 3.9 101.8 ± 5.1
AML
18.0 102.6 ± 4.3 100.7 ± 4.7
150.0 100.3 ± 3.9 98.9 ± 4.5
HCT
15.0 102.5 ± 4.5 101.9 ± 5.1
300.0 102.6 ± 4.3 100.7 ± 4.7
Long term stability
at –20 °C for 7 days
VAL
150.0 100.9 ± 3.8 99.9 ± 5.0
600.0 99.5 ± 3.0 99.3 ± 3.7
3000.0 101.4 ± 3.3 100.9 ± 4.2
AML
18.0 99.9 ± 3.8 99.3 ± 2.7
30.0 104.9 ± 1.0 104.3 ± 4.1
150.0 100.4 ± 3.3 99.6 ± 3.0
HCT
15.0 101.7 ± 3.7 101.1 ± 6.9
60.0 101.1 ± 5.8 101.2 ± 7.0
300.0 101.2 ± 5.6 100.4 ± 7.4
a Mean ± SD, n = 6.
RT – room temperature
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Robustness. – To determine the robustness of the developed method, mobile phase
pH, mobile phase gradient acetonitrile to buffer, flow-rate of mobile phase detection wa-
velength, injection volume and column temperature were deliberately altered and the
responses for VAL, AML and HCT were recorded. None of the modifications caused a
significant change in resolution between analytes, tailing factor and theorectical plates
(Table VI).
Determination of VAL, AML and HCT in spiked human plasma
The across mean recovery of three replicates of spiked plasma samples of 100, 400
and 1000 VAL, 8, 20 and 80 AML and 10, 40 and 100 HCT was calculated to be 98.2 ± 6.6,
97.6 ± 3.7 and 97.4 ± 6.4 %, respectively. The results of the study indicate that the method
is suitable for the assay of VAL, AML and HCT without any interference from the hu-
man plasma components.
CONCLUSIONS
In the present work, a simple, rapid and sensitive reversed phase HPLC method has
been developed and validated for simultaneous estimation of the triple combination of
VAL, AML and HCT in human plasma using a PDA detector. Validated method was
found to be accurate, precise and specific. Simple and reproducible sample extraction
procedure with the mixture of acetonitrile/methanol (50:50) offers acceptable recovery
for the drugs. Stability data shows that analytes were stable in short and long studies;
seven days (long term) was sufficient for the preliminary pharmacokinetic study of VAL,
AML and HCT. The LC-MS/MS method is obviously highly sensitive but the analysis
done by HPLC is suitable for the preliminary pharmacokinetic study. Detection of VAL,
AML and HCT at higher to moderate levels can be performed by this method and it can
be also used for guidance to the LC-MS/MS method.
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S A @ E T A K
Jednostavna RP-HPLC metoda za odre|ivanje kombinacije triju lijekova valsartana,
amlodipina i hidroklorotiazida u humanoj plazmi
RITESH N. SHARMA i SHYAM SUNDER PANCHOLI
U ovom radu opisana je i validirana jednostavna RP-HPLC metoda za odre|ivanje
valsartana (VAL), amlodipina (AML) i hidroklorotiazida (HCT) u humanoj plazmi. VAL,
AML i HCT su razlu~eni na koloni Gemini C18. Po~etni sastav mobilne faze bio je aceto-
nitril (20 %) i 10 mmol L–1 otopina amonijevog formijata (80 %, V/V, pH pode{en na
3,5 ± 0,2 pomo}u mravlje kiseline), a nakon 20 minuta 70 % acetonitrila i 30 % 10 mmol L–1
amonijevog formijata, uz protok od 1 mL min–1. Uzorci su pro~i{}eni talo`enjem protei-
na i ekstrakcijom. Telmisartan je upotrebljen kao unutarnji standard. Metoda je validi-
rana prema uputama USFDA i EMEA uz dobro reproducibilnost i linearnost: R = 0.9985
(VAL), 0.9964 (AML), and 0.9971 (HCT). Ponovljivost i intermedijarna preciznost bile su
u rasponu 2,2–8,1, odnosno 4,6–11,7 % za sve tri ljekovite tvari. Srednji povrat ekstrak-
cije iz humane plazme za ovu kombinaciju lijekova iznosila je 76,5 (VAL), 72,0 (AML) i
73,0 (HCT) %. Iako je LC-MS/MS metoda osjetljivija od HPLC metode, HPLC je prihvat-
ljiva za preliminarna farmakokineti~ka ispitivanja. Provedeni pokusi pokazuju da se pred-
lo`enom metodom mogu simultano odrediti sastavnice trostruke kombinacije lijekova u
humanoj plazmi. Predlo`ena metoda mo`e biti korisna smjernica za LC-MS/MS metodu.
Klju~ne rije~i: valsartan, amlodipin, hidroklorotiazid, RP-HPLC, talo`enje proteina, kombinacija tri
lijeka
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